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The Ets family of transcription factors regulate expression of multiple genes involved in tumour progression. The aim of this study was
to investigate the expression of Ets-1 in a large panel of human breast cancers and relate its levels to the parameters of tumour
progression and metastasis. Using RT–PCR, Ets-1 mRNA was detected in 30 out of 42 (71%) fibroadenomas and 131 out of 179
(73%) primary breast carcinomas. Similarly, levels of Ets-1 mRNA were not significantly different in fibroadenomas and primary breast
carcinomas. Using Western blotting, four forms of the Ets-1 protein were detected, that is, p33, p42, p51 and p52. Levels of both p51
and p52 but not p33 and p42 were present at significantly higher levels in the carcinomas compared to the fibroadenomas (for p51,
Po0.007; for p52, Po0.02; Mann–Whitney U-test). Levels of p52, p51 and p33 correlated significantly with uPA protein levels
(Po0.01), while only levels of p52 correlated significantly with HER-2/neu protein levels (Po0.01). Using immunohistochemistry, Ets-
1 was found predominantly in tumour cells, but was also detected in some stromal cells surrounding tumour islands. We conclude
that, while at the mRNA level, Ets-1 was found at similar levels in fibroadenomas and primary breast carcinomas, higher protein levels
were detected in the cancers compared to the benign specimens. Since p52, p51 and p33 correlate with uPA levels, these forms of
Ets-1 may play a role in breast cancer metastasis.
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E26 transformation-specific (Ets) genes encode a family of
transcription factors, which have been shown to regulate a diverse
array of biological functions (Wasylyk et al, 1993). The criterion
for membership of this family is an approximate 85-amino-acid
consensus motif known as the Ets domain (Papas et al, 1989;
Janknecht and Nordheim, 1993; Wasylyk et al, 1993; Mavrotha-
lassitis et al, 1994; Tymms and Kola, 1994). The Ets motif is
necessary for the specific recognition of a purine-rich core
sequence, GGAA/T, within the promoter/enhancer regions of
multiple target genes (Higashino et al, 1995; Himelstein et al,
1997). This domain appears to possess a unique structural motif
for binding DNA with high specificity (Wasylyk et al, 1993).
Amongst the genes whose promoter/enhancer regions contain Ets-
binding sites (EBSs) are several matrix-degrading proteases such
as the urokinase plasminogen activator (uPA), cathespin B, matrix
metalloproteinase (MMP)-1, MMP-3 and MMP-9 (White et al,
1997; Kitange et al, 1999; Sementchenko and Watson, 2000;
Behrens et al, 2001) and genes coding for adhesion proteins such
as specific integrins, cadherins and selectins (Sementchenko and
Watson, 2000).
Ets-1, the founder member of the Ets gene family, is located on
the long arm of chromosome 11 (11q23–q24). Ets-1 is the cellular
homologue of the v-Ets gene found in the avian erythroblastosis
virus E26 (Watson et al, 1990). In humans, the Ets-1 gene encodes
two mRNA transcripts, a full-length (6.8kb) transcript and an
alternatively spliced (2.7kb) transcript (Koizumi et al, 1990; Collyn
d’Hooghe et al, 1993). The full-length transcript encodes both a
51kDa protein and a 42kDa protein (Bhat et al, 1996). The 51kDa
protein can be phosphorylated as a result of increased intracellular
calcium levels, giving rise to a 52kDa protein (Bhat et al, 1996).
The 42kDa protein lacks exon VII, which contains the major
phosphorylation site in the full-length protein (Jorcyk et al, 1991).
Ets proteins are targets for phosphorylation in response to
stimulation by a variety of different growth modulators, including
intracellular calcium, activators of protein kinase C pathways,
growth factors and cytokines (Bhat et al, 1996). Variations in the
degree of activation of the Ets-1 protein seen in different cell types
may arise from differential phosphorylation or dephosphorylation
within a given cell (Pognonec et al, 1990).
In model systems, increased expression of Ets-1 was found to be
associated with enhanced angiogenesis and the invasive phenotype
(Vandenbunder et al, 1994a,b; Ito et al, 1998; Sato et al, 2000). In
addition, several angiogenic factors, such as the vascular
endothelial growth factor (VEGF) and both acidic and basic
fibroblast growth factor (FGF), have been shown to induce
expression of Ets-1 (Wernert et al, 1994; Sato et al, 2000). In a
preliminary report, Span et al (2002) recently showed that high
expression of Ets-1 was associated with adverse prognosis in breast
cancer. In that study, the authors also found a significant
correlation between Ets-1 levels and both VEGF and plasminogen
activator inhibitor-1 (PAI-1) (Span et al, 2002). All these findings,
taken together, suggest that Ets-1 is likely to play a key role in
cancer progression, especially angiogenesis and invasion.
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panel of human breast tissues using reverse transcriptase–
polymerase chain reaction (RT–PCR), Western blotting and
immunohistochemistry. We also related levels of Ets-1 to the
established prognostic factors for breast cancer and factors
involved in tumour progression, that is, urokinase plasminogen
activator (uPA) and human epidermal growth factor receptor 2
(HER-2/neu).
MATERIALS AND METHODS
Human breast tissues
Breast tissue specimens were obtained during surgery, and,
following histopathological examination, the remainder of each
sample was immediately frozen in liquid nitrogen. The samples
were then powdered using the Braun Mikrodismembrator (Braun
Apparate, Melsungen, Germany) and the powder stored at  801C
until further use. The characteristics of the breast cancers used in
this study are summarised in Table 1. In total, 179 primary breast
carcinomas were analysed for Ets-1 mRNA expression and of these
78 were randomly selected for analysis of Ets-1 protein expression.
In all, 42 fibroadenomas were analysed for Ets-1 mRNA
expression, 38 of which were tested for Ets-1 protein expression.
Immunohistochemistry was carried out on cryosections from
seven primary breast carcinomas and seven fibroadenomas. The
quality of each section and the relative cellular composition were
determined by histopathological assessment. Ethical approval for
this study was issued by the Ethics Committee, St Vincent’s
University Hospital, Dublin, Ireland.
RNA extraction
Total RNA was extracted from 100–200mg of breast tissue using
the guanidine isothiocyanate/phenol chloroform method (Chomc-
zynski and Sacchi, 1987). The integrity of the RNA was visualised
by running 10ml on a 2.5% agarose gel with ethidium bromide
staining and checking the integrity of the 28 S and 18 S bands. The
purity of RNA was determined by reading the absorbance at
260nm.
Complementary strand DNA (cDNA) synthesis
Total RNA (1mg) was reversed transcribed to single-stranded
cDNA in a final volume of 20ml. The reaction mixture contained
0.4mM of each deoxynucleotide triphosphates (dNTP), 10mgml
 1
of Oligo (dT)12–18,1 0 m M dithiolthreitol (DTT), 50mM Tris–HCl
(pH 8.3), 75mM KCL and 3mM MgCl2. This reaction mixture was
incubated for 5min at 701C to remove secondary RNA structures,
centrifuged and cooled on ice, followed by the addition of 4.6U of
human placenta ribonuclease inhibitor (GibcoBRL
s) and 200U of
Moloney murine leukaemia virus reverse transcriptase (Promega).
Samples were incubated for 1h at 371C and finally heated for 5min
at 651C. cDNA was stored aliquoted at  201C until required for
PCR amplification.
PCR
Semiquantitation of Ets-1 and uPA was performed following
co-amplification and normalisation with an internal control
sequence, glyceraldehydes-3-phosphate-dehydrogenase (GAPDH).
The primers for Ets-1 and GAPDH were designed and numbered
according to Genbank notation (Accession numbers¼NM_
005238, NM_002046). Primers specific for the amplification of
the transcripts were chosen using the ‘Primer Select’ software, and
the specificity confirmed by carrying out a detailed BLAST search.
Details of all primer pairs are as follows:
Ets-1: sense, 50-CGC TAT ACC TCG GAT TAC TT-30; antisense,
50-GTC ATA GGA GGG AAC ACG-30 (nucleotides 735–754 and
1113–1130, respectively).
GAPDH: sense, 50-CCA CCC ATG GCA AAA TTC CAT GGC A-
30; antisense, 50-TCT AGA CGG CAG GTC AGG TCC ACC-30
(nucleotides 227–250 and 801–824, respectively; Crofford et al,
1993).
The PCR reaction comprised of 2ml of cDNA template obtained
from 1mg of RNA, 100ng each of upstream and downstream
primers (Genosys, Pampisford, UK), 0.25mM each of dNTP,
2.0mM MgCl2 and 1.25U of Taq DNA polymerase (Promega) in
a reaction buffer made up to a final volume of 50ml. All PCR
reactions were performed in an automated thermocycler (MJ
Research, Watertown, MA, USA). The cycling conditions for each
of the primer sets were as follows:
Ets-1: A denaturing step for 2min at 941C, followed by 1min at
941C, 1min at 581C and 1min at 721C for 33 cycles, followed by
5min at 721C.
GAPDH: A denaturing step for 2min at 941C, followed by 1min
at 941C, 1min at 601C and 1min at 721C for 30 cycles, followed by
5min at 721C.
With these conditions, amplification products were obtained
in the exponential phase for both sets of primers used. Following
amplification, 20ml of PCR product from each reaction was
run out on a 2.5% agarose gel and visualised by ethidium
bromide staining under UV light. The intensity of the bands
was determined by densitometry (EagleEyet, Stratagene, UK),
and expressed as a ratio of the GAPDH band intensity, which
was used as an internal control. Negative controls included
omission of reverse transcriptase and replacement of cDNA
by water. The identity of the PCR products was confirmed
by direct sequencing (ABI prism 310 technology). For all
reactions, the product agreed with the expected sequence
X98%.
Table 1 Characteristics of breast cancers used
Variable n % positive
Nodal status
Negative 80 44.6
Positive 89 49.7
Unknown 10 5.7
Tumour size
T1 (p2cm) 45 25
T2 (2–5cm) 91 51
T3–4 (X5cm) 29 16
Unknown 14 8
Histology type
Ductal (D) 133 74.3
Lobular (L) 27 15
D & L 10 5.7
Unknown 9 5
ER status
a
Negative 50 28
Positive 128 71.5
Unknown 1 0.5
PR status
b
Negative 73 41
Positive 77 43
Unknown 29 16
ER¼oestrogen receptor. PR¼progesterone receptor.
aCutoff point¼200fmolg
 1
of wet weight tissue.
bCutoff point¼1000fmolg
 1 of wet weight tissue.
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Frozen powdered tissue samples were suspended in 50mM Tris–
HCl (pH 7.4) (2ml per 100mg of sample) containing Triton X-100
to a final concentration of 1% (vv
 1). These homogenates were
agitated for 20min at 41C and centrifuged at 13000g for 20min at
41C. The pellet was discarded and the supernatant containing the
protein was transferred to a clean tube. Total protein concentra-
tion was determined using the micro-bicinchoninic acid (BCA)
protein assay (Pierce, Rochford, IL, USA) according to the
manufacturer’s instructions. Samples each containing 30mgo f
protein, along with molecular weight marker (SeeBlue
TM Pre-
stained standards, Novex, USA) and a positive control for the
antibody (Jurkat cell lysate, Upstate Biotechnology, Lake Placid,
NY, USA), were subjected to 12% polyacrylamide gel electrophor-
esis under reducing conditions, and the proteins were transferred
to a nitrocellulose membrane (Sigma Chemical Company, St Louis,
MO, USA).
After nonspecific sites were blocked with 5% powdered milk in
0.05% Triton X-100/Tris-buffered saline (TBS-T) for 1h, blots were
incubated overnight with an IgG-purified rabbit polyclonal Ets-1
(C-20) antibody at a final concentration of 0.4mgml
 1 (Santa Cruz
Biotechnology, Inc) in a solution containing 5% powdered milk
and 0.05% Triton X-100/TBS. The blots were then washed three
times in TBS-T for 10min each and incubated with a HRP-
conjugated goat anti-rabbit IgG (Sigma-Aldrich Ireland Ltd,
Dublin, Ireland) at a concentration of 1mgml
 1 in 5% powdered
milk in 0.05% TBS-T. All samples were also blotted for b-actin
(Clone AC-15, Sigma-Aldrich, Ireland Ltd, Dublin, Ireland) to
normalise protein amounts. Bands were detected by the addition of
a chemiluminescent substrate (Luminol system, Santa Cruz
Biotechnology, Inc). Blots were exposed to Fuji X-ray film for
3min. Scanning densitometry was performed on the protein bands
using the EagleEyet Still Video system (EagleEyet, Stratagene,
UK) and arbitrary units assigned. Values are expressed as a ratio to
b-actin.
Immunohistochemistry
Breast tissue was placed directly in the cryopreservative embed-
ding media OCT compound (Tissue Tek, Sakura, Finetek, Europe
BV, Zoeterwoude, The Netherlands) and immediately frozen in
liquid nitrogen. Sections (7mm) were placed on glass slides coated
with 2% 3-amino-propyl-triethoxy-silane (Sigma-Aldrich Ireland
Ltd, Dublin, Ireland) in acetone and dried for 12h at room
temperature. Tissue sections were fixed in 1% paraformaldehyde,
air-dried and incubated for 15min at room temperature with
normal blocking serum (Vectastain Goat Elite Kit, Vector
Laboratories Ltd, Peterborough, UK). The primary antibody for
Ets-1 (C-20) was an IgG-purified rabbit polyclonal antibody raised
against the peptide mapping at the carboxy-terminus of human
Ets-1 (200mgml
 1; Santa Cruz Biotechnology, Inc). The primary
antibody was diluted 1:100 in 0.6 M NaCl. Following 1h incubation
of the primary antibody at room temperature, a biotinylated rabbit
secondary antibody (1:500) (Vector Laboratories, Burlingame,
CA, USA) was applied to the sections, followed by the avidin–
biotin–peroxidase complex (ABC kit, Vectastain, Burlingame, CA,
USA). Negative controls included preabsorption of the primary
antibody with an excess of corresponding synthetic peptide (sc-350
p, 100mg0.5
 1ml, Santa Cruz Biotechnology, Inc), and the use of
isotype-matched nonimmune rabbit IgG.
Immunofluorescent microscopy
Immunofluorescent microscopy was carried out using the same
procedure as that used for immunohistochemistry. Sections were
incubated in diluted normal goat serum (Vector Laboratories,
Burlingame, CA, USA). The primary polyclonal antibody for Ets-1
(C-20), as described previously, was diluted 1:10 in 10% normal
human serum and incubated for 60min. Sections were washed in
phosphate-buffered saline (PBS) and incubated for 30min in
biotinylated anti-rabbit secondary antibody (1:500, Vector
Laboratories, Burlingame, CA, USA). Slides were washed thor-
oughly in PBS, and incubated in a 1:100 dilution of Cy3
fluorochrome-conjugated monoclonal mouse anti-biotin antibody
(BN-34, Sigma Chemical Company, St Louis, MO, USA) for 30min.
This was added to bind the biotinylated anti-rabbit secondary
antibody. Following washing with PBS, the slides were mounted in
Dako
s fluorescent mounting medium (Dako Corporation, Car-
pinteria, CA, USA). Negative controls included the use of an
isotype-matched nonimmune rabbit IgG and omission of the
primary antibody.
Enzyme-linked immunosorbent assay (ELISA)
uPA ELISA kits were obtained from American Diagnostica Inc,
Greenwich, CT, USA; oestrogen receptor (ER) and progesterone
receptor (PR) ELISA kits were obtained from Abbott Diagnostics,
North Chicago, IL, USA, and the HER-2/neu ELISA kits were
obtained from Oncogene Research products, Cambridge, MA,
USA. The supernatants prepared for Western blotting were used in
the ELISA assays. All procedures were carried out using the
manufacturers’ recommended protocol. The cutoff values for ER
and PR were 200, and 1000fmolG
 1 wet weight tissue, respectively
(Cullen et al, 2001).
Statistical analysis
The strength of associations between the various parameters
measured in this study was tested using nonparametric tests,
which do not assume that the data are normally distributed.
Mann–Whitney U-tests were used for categorical data, and the
Spearman rank correlation was used for continuous variables.
Two-sided P-values below 0.05 were considered statistically
significant.
RESULTS
Expression of Ets-1 mRNA in fibroadenomas and primary
breast carcinomas
Representative expressions of Ets-1 and GAPDH mRNA detected
by RT–PCR are shown in Figure 1A. GAPDH was used as an
internal control and confirmed an equivalent amount of RNA
loading for each sample used. Ets-1 mRNA was expressed in
similar proportions of fibroadenomas (30 out of 42, 71%) and
primary breast carcinomas (131 out of 179, 73%) (P, NS). Although
levels tended to be higher in the carcinomas compared to the
fibroadenomas, this difference was not statistically significant
(Figure 1A,B).
Expression of Ets-1 protein in fibroadenomas and primary
breast carcinomas
Figure 2A shows Ets-1 protein expression measured by Western
blotting. In total, four different proteins were detected: p51, which
is regarded as full-length Ets-1, p52, which is thought to be a
phosphorylated form of Ets-1 (Koizumi et al, 1990), p42, which is
derived from a splice variant lacking exon VII (Bhat et al, 1996),
and p33. The p33 form of Ets-1 does not appear to have been
described previously in the literature. However, as this band was
eliminated in the presence of excess blocking peptide (sc-350 p,
100mg0.5
 1ml, Santa Cruz Biotechnology, Inc), (data not shown),
it is likely to be a form of Ets-1 or at least Ets-1 related.
Immunoreactivity of p42, p51 and p52 was also eliminated in the
presence of excess blocking peptide (data not shown).
Ets-1 transcription factor in human breast cancer
Y Buggy et al
1310
British Journal of Cancer (2004) 91(7), 1308–1315 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yTable 2 summarises the distribution of the four forms of
the Ets-1 protein in fibroadenomas and primary breast
carcinomas. For both carcinomas and fibroadenomas, the
predominant form was p52, followed by p33 and p51. In the
carcinomas, p42 was detected in only eight out of 78 (10%)
samples, while in the fibroadenomas this form was present in
five out of 38 (13%) samples. Levels of both p51 and p52, but not
p33, were significantly higher in carcinomas compared
to fibroadenomas (for p51, P¼0.007; for p52, P¼0.02;
Mann–Whitney U-test).
Typical immunostaining patterns for Ets-1 in primary
breast carcinoma tissue and fibroadenoma tissue sections are
shown in Figure 3. Haematoxylin and eosin-stained sections
were used to select the most cellular part of the tissue sections
and the area with the lowest architectural differentiation.
We found strong Ets-1 staining in the primary breast carcinoma
tissue sections (Figure 3A,B), especially on the tumour cells
(Figure 3B). Some stromal cell staining was also observed,
especially surrounding the tumour islands. Most of the Ets-1
staining was found to be nuclear, although some cytoplasmic
staining was also seen. In the fibroadenomas, epithelial and
stromal cell staining was also observed (Figure 3). The specificity
of Ets-1 antibody staining was confirmed by an absence of
reactivity on serial sections treated with Ets-1 antibody that had
been preincubated with an excess of specific antigen (result not
shown). Immunostaining with isotype-matched nonimmune rabbit
IgG yielded a complete absence of staining in all sections stained
(result not shown). Immunofluorescent microscopy was also
carried out on the primary breast carcinoma sections (n¼7).
Both nuclear and cytoplasmic localisations of Ets-1 were observed
(Figure 3C).
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Figure 2 (A) Ets-1 protein expression in primary carcinomas and
fibroadenomas. Levels of Ets-1 protein were determined by Western
blotting as described under ‘Materials and methods’. FA denotes
fibroadenoma tissue, Prim. denotes primary breast carcinomas and Pos.
denotes positive control (Jurkat cell lysate). Arrows show Ets-1 p51, p52,
p33 and p42 proteins detected using an Ets-1-specific antibody. (B)
Distribution of Ets-1 p52, p51 and p33 levels in primary carcinomas and
fibroadenomas as detected by Western blotting. Median levels are
indicated by the bars. Each dot represents a semiquantitative value
following scanning densitometry from one experiment. Values are
expressed as a ratio to b-actin.
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Figure 1 (A) Representative RT–PCR products of Ets-1 and GAPDH
detected in primary carcinomas and fibroadenomas; lane MW, 100 base
pair DNA ladder; lane 1, negative control without RT; lane 2, positive
control for RT–PCR. (B) Distribution of Ets-1 mRNA levels in
fibroadenoma tissue and primary breast carcinomas as detected by RT–
PCR. Median levels are indicated by the bars. Each dot represents a
semiquantitative value following scanning densitometry from one experi-
ment. Values are expressed as a ratio to GAPDH.
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Since uPA is causally involved in tumour progression (Duffy et al,
1988), we correlated its levels with those of Ets-1. As shown in
Figure 4, a statistically significant relationship was found to exist
between uPA and the 52, 51 and 33kDa forms of the Ets-1 protein
in the primary carcinomas (for p51, r¼0.38, P¼0.01; for p52,
r¼0.40, P¼0.01; for p33, r¼0.48, P¼0.002; Spearman rank
nonparametric test) (Figure 4A–C).
Relationship between Ets-1 and established prognostic
factors in breast cancer
Neither Ets-1 mRNA nor any form of the Ets-1 protein correlated
significantly with tumour size, nodal status, histology type ER or
PR levels (Table 3). Although there were relatively few matched
values for Ets-1 protein and HER-2/neu (n¼35), a significant
relationship was observed between the phosphorylated form of the
Ets-1 protein (52kDa) and HER-2/neu levels (r¼0.43, P¼0.01;
Spearman rank nonparametric test) (Figure 5). No significant
relationship however was found between p51, p33, p42 and HER-2/
neu levels.
DISCUSSION
Ets proteins regulate the expression of multiple genes involved in
cancer dissemination and have been associated with invasiveness
in model systems (Sementchenko and Watson, 2000). Despite this,
a distinct biological role for the Ets proteins in human cancer has
yet to be established. In this investigation, Ets-1 mRNA was found
Table 2 Distribution of the main forms of the Ets-1 protein in
fibroadenomas and primary breast carcinomas
Fibroadenoma (n¼38) Primary breast carcinoma (n¼78)
No. pos. % pos Median level No. pos. % pos Median level
p33 27 74 0.44 52 67 0.36
p42 5 13 0 8 10 0
p51 18 47 0 44 56 0.19
p52 32 84 0.18 65 83 0.44
A. B.
A
A
A B
A B
C D
E F
B
C D
B
C
Figure 3 (A) Ets-1 staining of frozen sections of fibroadenoma.
Immunohistochemical staining of fibroadenoma tissue showing Ets-1
protein distributution mainly around the lobules and ducts and also in
the stromal fibroblasts. Some negatively stained cells are also seen in the
surrounding stromal tissue. Immunoperoxidase staining of sections was
carried out using the Vectastain Elite ABC kit (Vector Laboratories) on
7mm sections of frozen breast tissue embedded in OCT according to the
manufacturer’s recommendations. (A) Fibroadenoma tissue section  20
(objective); (B) rabbit IgG-negative control  20 (objective); (C)  40
showing Ets-1 staining in the epithelial cells lining the ducts and also in the
surrounding stroma; (D) IgG control  40. (B) Ets-1 staining of frozen
sections of breast tumour tissue. Immunohistochemical staining of breast
tumour tissue showing Ets-1 protein distributution mainly in the tumour
cells and to a lesser extent in the stromal fibroblasts surrounding the
tumour islands. Some negatively stained cells are also seen in the
surrounding stromal tissue. Immunoperoxidase staining of sections was
carried out using the Vectastain Elite ABC kit (Vector Laboratories) on
7mm sections of frozen breast tissue embedded in OCT according to the
manufacturer’s recommendations. (A) Breast tumour tissue section  20
(objective); (B) rabbit IgG negative control  20 (objective); (C)  40
showing Ets-1 staining in the tumour cells; (D) IgG control  40; (E)  60
showing a cluster of tumour cells stained positively for Ets-1; (F) IgG control
 60. (C) Localisation of Ets-1 protein in breast tumour tissue by
immunofluorescent microscopy. Ets-1 staining is observed in both the
nucleus and cytoplasm of the tumour cells in the primary breast cancer
tissue sections. (A) Arrow shows Ets-1 cytoplasmic staining (original
magnification  200); (B) arrow shows Ets-1 nuclear staining.
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fibroadenomas. In contrast to findings at the mRNA level,
concentrations of the two main protein forms of Ets-1, that is,
p51 and p52, were significantly increased in carcinomas compared
to the fibroadenomas. The increase in expression of Ets-1 protein
compared to Ets-1 mRNA in the primary carcinomas may relate to
enhanced translation in the malignant vs the benign tissues.
Previously, using in situ hybridisation, mRNA for Ets-1 was
reported to be increased in invasive breast cancers vis-a `-vis in in
situ lesions (Behrens et al, 2001). To our knowledge, no previous
report has compared Ets-1 expression in fibroadenomas and
carcinomas.
In addition to p51 and p52, two further forms of the Ets-1
protein, that is, p42 and p33, were detected in the present
investigation. p42 is derived from an mRNA splice variant lacking
exon VII and has previously been detected in both benign and
malignant breast tumours (Behrens et al, 2001). In MDA-MB-231
breast cancer cells but not MCF-7 cells, overexpression of the p42
form of Ets-1 was found to reduce cell survival (Ballschmieter et al,
2003). On the other hand, in colon cancer cells, the p42 form of the
Ets-1 protein was shown to rescue Fas-induced apoptosis (Li et al,
1999). The p33 protein band reported here does not appear to have
been described previously, and its identity remains unknown. A
p39 form of Ets-1 previously reported by Koizumi et al (1990) was
not detected in this study. This form of the Ets-1 protein is thought
to be derived from the p51 protein by covalent modification of the
protein by a synthetic protease inhibitor and thus may be a
product of the specific extraction method (Fisher et al, 1992).
In this investigation, we found the Ets-1 protein to be present in
both tumour and stromal cells, especially when the latter
surrounded tumour islands. Using both immunohistochemistry
and in situ hybridisation, Behrens et al (2001) detected expression
of Ets-1 in stromal fibroblasts, endothelial cells and epithelial cells
in breast cancers. In the endothelial cells, upregulation occurred
during the onset of angiogenesis around the in situ carcinoma. In
ovarian (Davidson et al, 2001) and lung carcinomas (Bolon et al,
1995), expression of Ets-1 has also been observed in both stromal
and tumour cells. In oral squamous cell cancers, Ets-1 was found in
endothelial cells of well-vascularised tumours (Pande et al, 1999).
In the present study, no significant correlation was found
between Ets-1 expression and either tumour size, nodal status, ER
or PR status. In colorectal cancer, however, expression of Ets-1
protein was found to be significantly associated with lymph node
status, depth of invasion and lymphatic invasion (Nakayama et al,
2001). Also, in lung cancer, Ets-1 protein levels correlated with
tumour size, lymph node status and tumour stage (Bolon et al,
1995).
Although no significant relationship was found between Ets-1
expression and established prognostic factors in this study, the
p33, p51 and p52 forms of the Ets-1 protein correlated significantly
with uPA levels. uPA is a serine protease causally involved in
invasion and metastasis, and is one of the most potent biological
prognostic factors so far described in breast cancer (Duffy et al,
1998). Recently, its prognostic value was also validated for node-
negative breast cancer patients using two different level 1 evidence
studies, that is, in both a randomised prospective trial (Foekens
et al, 2000) and a pooled analysis (Look et al, 2002). Consistent
with our studies showing a significant relationship between Ets-1
and uPA, Span et al (2002) recently reported an association
between Ets-1 and poor prognosis in breast cancer. In contrast to
our results, Span et al (2002) found no significant correlation
between Ets-1 and uPA in breast cancer. A significant relationship,
however, was found between Ets-1 and PAI-1, an inhibitor of uPA
(Span et al, 2002). The significant correlation between Ets-1
proteins, that is, p52, p51, p33 and uPA, in this study is consistent
with previous reports showing the presence of EBSs in the
enhancer/promoter elements of the uPA gene (Watabe et al, 1998;
Sementchenko and Watson, 2000). Indeed, evidence from multiple
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Figure 4 Relationship between Ets-1 52kDa and uPA protein (A) and
Ets-1 51kDa protein and uPA (B) and Ets-1 33kDa and uPA (C). Ets-1
protein measurements were carried out using Western blotting. Arbitrary
units were assigned to each protein band following scanning densitometry.
Values are expressed as a ratio to b-actin. uPA protein was measured using
ELISA. Data was analysed using the nonparametric Spearman rank test.
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Figure 5 Relationship between Ets-1 52kDa protein and HER-2/neu
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 1). Ets-1 protein measurements were carried out using Western
blotting. Arbitrary units were assigned to each protein band following
scanning densitometry. Values are expressed as a ratio to b-actin. HER-2/
neu levels were measured using ELISA. Data was analysed using the
nonparametric Spearman rank test.
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ymodel systems suggest that the Ets-1 transcription factor may be
one of the important regulators controlling the involvement of
uPA in the invasive process (Watabe et al, 1998; Nakada et al,
1999; Sementchenko and Watson, 2000).
In addition to correlating with uPA, we also found a significant
relationship between the p52 form of Ets-1 and HER-2/neu. HER-
2/neu is a proto-oncogene overexpressed in 15–30% of invasive
breast cancers (Slamon et al, 1989). In model systems, over-
expression has been associated with both tumorigenesis and
metastasis (Slamon and Clark, 1988). In human breast cancers,
increased levels are generally associated with adverse outcome
(Allred et al, 1992). Previously, another member of the Ets family,
that is, PEA3, was also found to correlate with HER-2/neu in breast
cancer (Shepherd et al, 2001) and EBSs have been found in the
HER-2/neu promoter (Chiang et al, 2000). Our finding of a
correlation between Ets-1 protein levels and both HER-2/neu and
uPA is consistent with previous data showing a role for Ets-1 in
invasive processes (Vandenbunder et al, 1994a; Wernert et al,
1994; Nakada et al, 1999; Pande et al, 1999; Kitange et al, 2000;
Naito et al, 2000).
In conclusion, this is one of the most detailed reports to
date on an Ets protein in a human cancer. Our results show
that certain forms of the Ets-1 protein, that is, p52 and p51,
are expressed at much higher levels in breast cancer compared
to fibroadenomas. Since multiple signalling pathways con-
verge on Ets transcription factors (Wasylyk et al, 1998), the
latter should be logical targets for new anticancer agents.
Finally, since Ets-1 proteins correlate with both uPA and
HER-2/neu, high levels are likely to be associated with aggressive
disease.
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